亚太地区癫痫市场预测至 2030 年 - 区域分析 - 按类型（渐进性肌阵挛性癫痫、反射性癫痫、全身性癫痫等）、给药途径（口服、肠胃外等）、治疗类型（第一代药物、第二代药物和第三代药物）、年龄组（成人和儿童）和分销渠道（医院药房、零售药房等）

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030

No. of Pages: 146    |    Report Code: BMIRE00030724    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Asia Pacific Epilepsy Market
Free Sample Buy Now
2022 年亚太地区癫痫市场价值为 22.0092 亿美元，预计到 2030 年将达到 31.4344 亿美元；预计 2022 年至 2030 年的复合年增长率为 4.6%。

组织开展的宣传计划激增，推动亚太地区癫痫市场发展

人们对癫痫、其症状以及早期诊断重要性的认识不断提高，导致就医患者数量激增。癫痫基金会、癫痫学会、美国癫痫学会和中佛罗里达癫痫协会等组织在教育人们了解这种疾病方面发挥着至关重要的作用。这些组织的参与提高了诊断率，并扩大了需要癫痫治疗的患者群体。世界各地的组织开展了大量宣传活动，以传播有关这种疾病和可用治疗方法的认识。 2023 年，在癫痫紫色日，海得拉巴（印度）的 Aster Prime 医院与 Krishna Kant Park 步行者协会合作举办了一场宣传活动。共有 150 名参与者（包括步行者和瑜伽练习者）参加了此次活动。此外，为了提高患有癫痫的澳大利亚人的生活质量，澳大利亚癫痫行动组织提供了各种工具和服务，旨在提高认识、教育和为个人提供必要的技能。因此，此类举措和宣传活动可增加癫痫诊断和治疗，为市场提供丰厚的增长机会。

亚太癫痫市场概览

亚太癫痫市场基于中国、日本、印度、澳大利亚、韩国和亚太地区其他地区进行分析。根据世界卫生组织 (WHO) 的报告，癫痫在发展中国家比在发达国家更为常见，患病率分别为 6.1% 和 5.0%。

亚太地区癫痫市场收入及预测至 2030 年（百万美元）

亚太地区癫痫市场细分

亚太地区癫痫市场分为类型、给药途径、治疗类型、年龄组、分销渠道和国家。

根据类型，亚太地区癫痫市场分为进行性肌阵挛性癫痫、反射性癫痫、全身性癫痫和其他。全身性癫痫细分市场在 2022 年占据了最大的市场份额。

就给药途径而言，亚太地区癫痫市场分为口服、肠外和其他。口服药物在 2022 年占据了最大的市场份额。

按治疗类型，亚太癫痫市场分为第一代药物、第二代药物和第三代药物。第三代药物在 2022 年占据了最大的市场份额。

根据年龄组，亚太癫痫市场分为成人和儿童。成人部分在 2022 年占据了更大的市场份额。

在分销渠道方面，亚太癫痫市场分为医院药房、零售药房和其他。医院药房部分在 2022 年占据了最大的市场份额。

按国家/地区，亚太癫痫市场分为中国、日本、印度、澳大利亚、韩国和亚太地区其他地区。 2022 年，中国占据了亚太地区癫痫市场的主导份额。

雅培实验室、辉瑞公司、卫材株式会社、UCB SA、LivaNova Plc、诺华公司、美敦力公司、葛兰素史克公司和 H. Lundbeck AS 是亚太地区癫痫市场的一些领先公司。

Asia Pacific Epilepsy Strategic Insights

Strategic insights for Asia Pacific Epilepsy involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-epilepsy-market-strategic-framework.webp
Get more information on this report

Asia Pacific Epilepsy Report Scope

Report Attribute Details
Market size in 2022 US$ 2,200.92 Million
Market Size by 2030 US$ 3,143.44 Million
Global CAGR (2022 - 2030) 4.6%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 类型
  • 进行性肌阵挛性癫痫
  • 反射性癫痫
  • 全身性癫痫
By 给药途径
  • 口服
  • 肠胃外
By 年龄组
  • 成人和儿童
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • Abbott Laboratories
  • Pfizer Inc
  • Eisai Co Ltd
  • UCB SA
  • LivaNova Plc
  • Novartis AG
  • Medtronic Plc
  • GSK Plc
  • H. Lundbeck AS
    		•
    Get more information on this report

    Asia Pacific Epilepsy Regional Insights

    The regional scope of Asia Pacific Epilepsy refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-epilepsy-market-geography.webp
    Get more information on this report
    Identical Market Reports with other Region/Countries

    The List of Companies - Asia Pacific Epilepsy Market

    1. Abbott Laboratories
    2. Pfizer Inc
    3. Eisai Co Ltd
    4. UCB SA
    5. LivaNova Plc
    6. Novartis AG
    7. Medtronic Plc
    8. GSK Plc
    9. H. Lundbeck AS
    Frequently Asked Questions
    How big is the Asia Pacific Epilepsy Market?

    The Asia Pacific Epilepsy Market is valued at US$ 2,200.92 Million in 2022, it is projected to reach US$ 3,143.44 Million by 2030.

    What is the CAGR for Asia Pacific Epilepsy Market by (2022 - 2030)?

    As per our report Asia Pacific Epilepsy Market, the market size is valued at US$ 2,200.92 Million in 2022, projecting it to reach US$ 3,143.44 Million by 2030. This translates to a CAGR of approximately 4.6% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Epilepsy Market report typically cover these key segments-

  • 类型 (进行性肌阵挛性癫痫, 反射性癫痫, 全身性癫痫)
  • 给药途径 (口服, 肠胃外)
  • 年龄组 (成人和儿童)

    • What is the historic period, base year, and forecast period taken for Asia Pacific Epilepsy Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Epilepsy Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
    • Who are the major players in Asia Pacific Epilepsy Market?

    The Asia Pacific Epilepsy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Abbott Laboratories
  • Pfizer Inc
  • Eisai Co Ltd
  • UCB SA
  • LivaNova Plc
  • Novartis AG
  • Medtronic Plc
  • GSK Plc
  • H. Lundbeck AS
    • Who should buy this report?

    The Asia Pacific Epilepsy Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Epilepsy Market value chain can benefit from the information contained in a comprehensive market report.

    asia-pacific-epilepsy-market